SolaVAX: Novel platform produces vaccines with inactivated viral particles
Researchers at Colorado State University have developed a vaccine for COVID-19 produced through a novel method (SolaVAX™) for inactivation of a whole virion particle. The vaccine has been tested in a sensitive hamster animal model for its ability to prevent infection upon challenge with SARS-CoV-2 virus and has been demonstrated to be effective in providing protection against COVID-19 disease.
The use of this methodology may afford a means to rapidly produce vaccine candidates in response to both emergent and existing disease threats. Due to the specificity of the chemistry, the ability to achieve inactivation using this photochemical method may have several significant advantages over the approaches used today which utilize chemical agents such as formalin, Beta propiolactone and ethyleneimine derivatives.
This may make possible the production of vaccine candidates with much better immunogen profiles than existing and includes the potential to extend such an approach to agents that may recalcitrant with regard to current technology.
- Ability to produce vaccines with high immunogenicity at low immunogen doses. This is exemplified by COVID-19 Vaccine induced potent immune response with relatively low doses of immunogen
- Vaccine candidates produced using this method are fully attenuated with regard to replication capabilities while maintaining viral protein structural integrity as close to the native virus as possible
- Well-established safety toxicology profile for chemicals and components used in the vaccine manufacturing process, i.e., non-mutagenic and non-carcinogenic materials that pose little to no toxicity or disposal risk to facility personnel or the environment in contrast to conventional methods for producing inactivated vaccine candidates.
- Safety profile of materials and methods has been documented extensively in pre-clinical and clinical programs in human subjects through clinical use of products in blood safety applications dating from 2007 to present.
- Rapid and affordable production of the inactivated vaccine is both practical and cost-effective. Raw material costs and production time is minimal for even bulk production of vaccine candidates.
- Utilizes existing equipment, reagents and disposables that are in routine use for treatment of blood products. Equipment is commercially available and in widespread, global distribution and use.